26 Mar 2020
NITROSAMINES – RISK EVALUATION EXTENDED TO OCTOBER 2020
EMA has published an update on their website extending the completion date for the risk assessment of nitrosamines – step 1. The new submission deadline is the 1st of October 2020, more information is expected to be published tomorrow.
16 Mar 2020
COVID-19 - Business Continuity Plan Activation
Following recent developments and immediately after WHO announcement of COVID-19 virus outbreak classification as a pandemic, OWLPHARMA has decided to activate its business continuity plan.
21 Feb 2020
Safety Assessment of Cosmetic Products
Regulation (EC) no. 1223/2009 stipulates that all cosmetic products, prior to being marketed in the EU, must undergo a safety assessment carried out by a qualified person. The assessment must always be kept up to date, and any relevant information generated after the product is placed on the market has to be taken into account.
6 Feb 2020
Estamos a recrutar - Medical Writer
A OWLpharma tem em aberto uma vaga para Medical Writer no Departamento Médico-Científico, em Coimbra.